Articles published by PharmaTher Holdings Ltd.
PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
January 18, 2023
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
November 14, 2022
PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
October 05, 2022
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following